Previous Close | 1.2130 |
Open | 1.3390 |
Bid | 1.3500 x 50000 |
Ask | 1.3780 x 50000 |
Day's Range | 1.3390 - 1.3390 |
52 Week Range | 0.3901 - 1.5460 |
Volume | |
Avg. Volume | 2,077 |
Market Cap | 284.046M |
Beta (5Y Monthly) | 0.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.